Status:

UNKNOWN

Comparison of the Effectiveness of Treatment With Mifepristone and Misoprostol at the Same Time Compared to the Administration of Drugs at a 48-hour Interval for Medical Abortion.

Lead Sponsor:

HaEmek Medical Center, Israel

Conditions:

Early Pregnancy

Eligibility:

FEMALE

18+ years

Phase:

NA

Brief Summary

Medical termination of pregnancy is a common and safe alternative to surgical termination of pregnancy(8). The current protocol in the investigators unit includes oral administration of Mifepristone 6...

Detailed Description

Medical termination of pregnancy is a common and safe alternative to surgical termination of pregnancy(8). According to the original protocol ,the administration of oral Mifepristone 600 mg is followe...

Eligibility Criteria

Inclusion

  • intrauterine singleton pregnancy of less than 49 days, reassured by ultrasound examination
  • patient who desire to terminate their pregnancy and have approval of the committee for termination of pregnancy
  • patient who gave their consent to have a surgical abortion eventual if needed

Exclusion

  • contraindication to Mifepristone or Misoprostol
  • suspected ectopic pregnancy
  • systemic treatment with steroids
  • adrenal insufficiency
  • heart and blood vessels disease
  • coagulopathy or use of anti-thrombotic agents
  • uncontrolled asthma
  • liver or kidney insufficiency
  • anorexia
  • intrauterine device
  • breastfeeding

Key Trial Info

Start Date :

March 1 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 30 2023

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT03440866

Start Date

March 1 2018

End Date

December 30 2023

Last Update

December 1 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

HaEmek medical center

Afula, Israel